Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) reports on events occurring on August 15, 2020, with the report filed on August 20, 2020. The filing details the entry into a material definitive agreement involving a strategic financing collaboration with affiliates of The Blackstone Group Inc. to support the clinical development of the Company's RNA interference (RNAi) therapeutics.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins for a reporting period. Instead, it outlines a specific funding arrangement:
- Total Funding Commitment: Up to $150 million from Blackstone.
- vutrisiran Allocation: Up to $70 million committed for the HELIOS-B Phase 3 clinical trial.
- ALN-AGT Allocation: Up to $26 million for a Phase 2 trial (right, not obligation) and up to $54 million for a Phase 3 trial (right, not obligation).
- Consideration to Blackstone:
- vutrisiran: 1% royalty on net sales and tranched payments upon regulatory approval.
- ALN-AGT: Tranched payments upon successful Phase 2 completion and regulatory approval.
- Security: Payment obligations are secured by security interests in specific intellectual property and a dedicated bank account.
Material Changes Versus Prior Period
This filing represents a new material agreement rather than a change in historical financial performance. The Company amended its existing Credit Agreement dated April 10, 2020, to add intellectual property relating to ALN-AGT as collateral. Alnylam retains sole responsibility for the development and commercialization of both vutrisiran and ALN-AGT.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Governance: The funding arrangement is governed by a joint steering committee with equal representation from both parties. The Company intends to file the full text of the agreements as exhibits to its Form 10-Q for the quarter ending September 30, 2020.
Risks and Termination Rights:
- Either party may terminate the agreement in the event of bankruptcy or uncured material breach.
- Blackstone may terminate if regulatory approval is not obtained, if clinical endpoints are not achieved, or upon a change of control of the Company.
- Termination may trigger obligations for the Company to repay development funding received and potentially continue tranched payments or royalties if regulatory approval is subsequently obtained.
Key Facts for Investor Verification
- Verify the specific terms of the tranched payments and the calculation of the "agreed multiple" of Blackstone's investment.
- Confirm the impact of the new security interests on the Company's existing Credit Agreement and overall debt capacity.
- Monitor the progress of the HELIOS-B Phase 3 trial for vutrisiran and the Phase 2/3 trials for ALN-AGT to assess funding drawdowns.
- Review the upcoming Form 10-Q for the full text of the Co-Development Agreement and the First Amendment to the Credit Agreement.